Influence of body weight and body mass index on the chronic pharmacokinetic and pharmacodynamic responses to clinically available doses of ticagrelor in patients with chronic coronary syndromes
Vascular Pharmacology · 2023
DOI: 10.1016/j.vph.2023.107145 ↗Kurz gefasst
Fachartikel in der Zeitschrift Vascular Pharmacology, 2023. Verfasst von William A E Parker und 11 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular Research Unit, Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK. Electronic addres…. Hauptthemen laut MEDLINE: Purinergic P2Y Receptor Antagonists, Platelet Aggregation. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: British Heart Foundation, AstraZeneca.
Abstract (Originalsprache)
Ticagrelor has multiple indications, including for some patients with chronic coronary syndromes (CCS) at high risk of ischaemic events. Body mass can potentially affect pharmacodynamics (PD) and pharmacokinetics (PK). We investigated the influence of body mass (range 53-172 kg, 20.8-46.9 kg/m2) on PD/PK in 221 CCS patients receiving ticagrelor 60 mg or 90 mg twice-daily (BD) during two randomised-controlled trials. Correlations between body weight (BW) or body mass index (BMI) and PD/PK measurements obtained during maintenance treatment at trough ('pre-dose') and peak effect ('post-dose') were assessed. BW and BMI correlated with P2Y12 reactivity units at pre-dose (e.g. BW:R = 0.26, p = 0.008) but not post-dose timepoints. BW affected ticagrelor active metabolite (TAM) levels (e.g. 60 mg BD, post-dose:R = -0.39, p < 0.0001) and there was evidence of an inverse power law relationship between BW and TAM-to-ticagrelor ratio. PK with ticagrelor 60 mg correlated significantly with BMI. BW and BMI did not affect the chance of high platelet reactivity, which remained very low across the whole cohort. There was no difference in PRU between the two doses of ticagrelor within each weight or BMI group. Body mass has modest effects on the PK/PD response to ticagrelor in patients with CCS but currently-used regimens appear adequate across the range of BW/BMI studied.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cardiovascular Research Unit, Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK. Electronic address: w.parker@sheffield.ac.uk.
- Division of Cardiology, University of Florida College of Medicine, Jacksonville, FL, USA.
- Department of Medicine, University of Colorado School of Medicine, Aurora, CO, USA.
- Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
- Université Paris-Cité, INSERM UMR1148/LVTS, AP-HP, Hôpital Bichat, Paris, France.
- Department of Cardiology, St John of God Hospital, Southwest Health Campus, Bunbury, WA, Australia.
Förderung
- British Heart Foundation
- AstraZeneca
Zitieren
APA
Parker, W. A. E., Angiolillo, D. J., Rollini, F., Franchi, F., Bonaca, M. P., Bhatt, D. L., Steg, P. G., Orme, R. C., Thomas, M. R., Judge, H. M., Sabatine, M. S., & Storey, R. F. (2023). Influence of body weight and body mass index on the chronic pharmacokinetic and pharmacodynamic responses to clinically available doses of ticagrelor in patients with chronic coronary syndromes. Vascular Pharmacology. https://doi.org/10.1016/j.vph.2023.107145
Vancouver
Parker WAE, Angiolillo DJ, Rollini F, Franchi F, Bonaca MP, Bhatt DL, et al. Influence of body weight and body mass index on the chronic pharmacokinetic and pharmacodynamic responses to clinically available doses of ticagrelor in patients with chronic coronary syndromes. Vascular Pharmacology. 2023. doi:10.1016/j.vph.2023.107145
BibTeX
@article{Parker2023,
author = {Parker, William A E and Angiolillo, Dominick J and Rollini, Fabiana and Franchi, Francesco and Bonaca, Marc P and Bhatt, Deepak L and Steg, Ph Gabriel and Orme, Rachel C and Thomas, Mark R and Judge, Heather M and Sabatine, Marc S and Storey, Robert F},
title = {Influence of body weight and body mass index on the chronic pharmacokinetic and pharmacodynamic responses to clinically available doses of ticagrelor in patients with chronic coronary syndromes},
journal = {Vascular Pharmacology},
year = {2023},
doi = {10.1016/j.vph.2023.107145}
}
EUVIMED